Myorisan?

What is Myorisan?
Myorisan is a veterinary non‑steroidal anti‑inflammatory drug (NSAID) used mainly to relieve pain and inflammation after orthopedic surgery in dogs. Its active ingredient is the selective COX‑2 inhibitor meloxicam.

How do veterinarians give it to pets?
Myorisan comes as a chewable tablet that owners can administer orally. The tablet is dissolved in a small amount of water if needed, but most dogs accept the chewable form directly.

What’s the recommended dose?
The usual dose is 0.05 mg of meloxicam per kilogram of body weight, given once daily. The treatment period typically lasts 5–7 days after surgery, though the exact duration may be adjusted by the veterinarian based on the dog’s response and health status.

What side effects do owners often report?
Common adverse effects include gastrointestinal upset (vomiting, diarrhea), loss of appetite, and mild lethargy. Less frequently, owners notice elevated liver enzymes or increased bleeding tendency, especially in dogs with pre‑existing conditions or those on blood‑thinning medications.

How does Myorisan compare to other canine NSAIDs?
Like Metacam (also meloxicam) and Rimadyl (carprofen), Myorisan provides good pain relief with a relatively low risk of kidney damage. Some owners prefer Myorisan because the chewable form is easier to give than the liquid or tablet versions of other brands.

Who makes Myorisan and is it still sold?
The drug is produced by a veterinary‑focused pharmaceutical company that distributes it in select markets. Availability varies by country; in many places it has been phased out in favor of newer meloxicam products with longer shelf lives and broader distribution.

When does the patent on Myorisan expire?
The core patent covering the meloxicam formulation has already expired, and the specific brand patent on Myorisan is no longer active. This means other manufacturers can produce generic versions of the same formulation, although the proprietary chewable delivery system may still be protected under separate patents. [1]

Can a generic version appear before the drug is discontinued?
Because the core patent has lapsed, a generic formulation could enter the market, but any unique delivery technology (the chewable tablet) would still be protected until its associated patents expire. Competition is likely to increase as more companies seek to offer similar products.

Where can owners find reliable product information?
Veterinary drug references, the drug’s prescribing information sheet, and the manufacturer’s website are the best sources for up‑to‑date dosing guidelines and safety warnings. For patent and regulatory status, DrugPatentWatch.com provides current details.